Healthcare
Live Price
Offline$94.81
-0.52% today
1Y Change
+564.40%
Window
Jun 30, 2025 → Jun 26, 2026
Coverage: 249 bars · Jun 30, 2025 → Jun 26, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Inhibrx Biosciences, Inc. (INBX) is a Healthcare stock with a market cap of $1.89B and listed on NASDAQ. The stock last traded around $94.81 and up 564.4% across the available one-year price window (Jun 30, 2025 → Jun 26, 2026). Baseline metrics include revenue growth of +550.0%, EPS growth of -107.8%, a dividend yield of 0.0%. What stands out right now is revenue +550.0%, EPS -107.8%, free cash flow +34.1% with operating margin -10386.5% and ROIC -117.4%. Valuation already assumes a fairly strong business story at price/sales 1451.8. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines INBX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
Relative Read
INBX is 546.41 pts ahead over the shared 1Y window.
INBX had 29.52 pts deeper max drawdown than SPY.
INBX beat SPY in 2 of 2 calendar years shown and trailed in 0.
INBX
+564.40%
Normalized return
SPY
+17.99%
S&P 500
Excess Return
+546.41 pts
Relative to SPY
INBX Max Drawdown
-38.66%
Trailing 1Y
SPY Max Drawdown
-9.13%
Trailing 1Y
Uses the longest available daily history for INBX and SPY.
| Year | INBX | SPY | Excess | Leader |
|---|---|---|---|---|
| 2026 | +26.35% | +6.71% | +19.64 pts | INBX |
| 2025 | +446.46% | +11.19% | +435.27 pts | INBX |
Unable to load analyst forecasts.
Timed out loading forecasts for INBX
Next Step
Forecasts are most valuable when they sit beside comparisons, earnings setup, and the rest of the business story.